TY - JOUR
T1 - Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome
AU - Allahyari, Abolghasem
AU - Seddigh-Shamsi, Mohsen
AU - Mahmoudi, Mahmoud
AU - Amel Jamehdar, Saeid
AU - Amini, Mahnaz
AU - Mozdourian, Mahnaz
AU - Javidarabshahi, Zahra
AU - Eslami Hasan Abadi, Saeed
AU - Amini, Shahram
AU - Sedaghat, Alireza
AU - Emadzadeh, Maryam
AU - Moeini Nodeh, Mohammad
AU - Rahimi, Hossein
AU - Bari, Alireza
AU - Mozaheb, Zahra
AU - Kamandi, Mostafa
AU - Ataei Azimi, Sajad
AU - Abrishami, Mojtaba
AU - Akbarian, Arezoo
AU - Ataei, Parisa
AU - Allahyari, Negin
AU - Hasanzadeh, Sepideh
AU - Saeedian, Neda
N1 - Funding Information:
Authors would love to thank everyone who supported this study especially the president of Mashhad University of Medical Sciences, vice president for research and technology, manager of Imam Reza Hospital and also all the donors for their kind contribution. Funding: This work was supported by Mashhad University of Medical Sciences.
Funding Information:
Funding: This work was supported by Mashhad University of Medical Sciences.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Since SARS-CoV-2 infection is rapidly spreading all around the world, affecting many people and exhausting health care resources, therapeutic options must be quickly investigated in order to develop a safe and effective treatment. The present study was designed to evaluate the safety and efficacy of convalescent plasma (CP) for treating severe cases of COVID-19 who developed acute respiratory distress syndrome (ARDS). Among 64 confirmed cases of severe COVID-19 with ARDS in this study, 32 patients received CP besides first line treatment. Their clinical response and outcome in regard to disease severity and mortality rate were evaluated and compared with the other 32 patients in the control group who were historically matched while randomly chosen from previous patients with the same conditions except for receiving CP therapy. Analysis of the data was performed using SPSS software. Patients with plasma therapy showed improvements in their clinical outcomes including a reduction in disease severity in terms of SOFA and APACHE II scores, the length of ICU stay, need for noninvasive ventilation and intubation and also showed an increase in oxygenation. They also showed reduction in mortality which was statistically significant in less severe cases with mild or moderate ARDS. Early administration of the convalescent plasma could successfully contribute to the treatment of severe COVID-19 patients with mild or moderate ARDS at risk of progressing to critical state.
AB - Since SARS-CoV-2 infection is rapidly spreading all around the world, affecting many people and exhausting health care resources, therapeutic options must be quickly investigated in order to develop a safe and effective treatment. The present study was designed to evaluate the safety and efficacy of convalescent plasma (CP) for treating severe cases of COVID-19 who developed acute respiratory distress syndrome (ARDS). Among 64 confirmed cases of severe COVID-19 with ARDS in this study, 32 patients received CP besides first line treatment. Their clinical response and outcome in regard to disease severity and mortality rate were evaluated and compared with the other 32 patients in the control group who were historically matched while randomly chosen from previous patients with the same conditions except for receiving CP therapy. Analysis of the data was performed using SPSS software. Patients with plasma therapy showed improvements in their clinical outcomes including a reduction in disease severity in terms of SOFA and APACHE II scores, the length of ICU stay, need for noninvasive ventilation and intubation and also showed an increase in oxygenation. They also showed reduction in mortality which was statistically significant in less severe cases with mild or moderate ARDS. Early administration of the convalescent plasma could successfully contribute to the treatment of severe COVID-19 patients with mild or moderate ARDS at risk of progressing to critical state.
KW - ARDS
KW - COVID-19
KW - Convalescent plasma
KW - Passive immunization
UR - https://www.scopus.com/pages/publications/85101223695
U2 - 10.1016/j.intimp.2020.107239
DO - 10.1016/j.intimp.2020.107239
M3 - Article
C2 - 33582019
SN - 1567-5769
VL - 93
JO - International immunopharmacology
JF - International immunopharmacology
M1 - 107239
ER -
SDG 3 Good Health and Well-being